A novel role of prognostic nutritional index in predicting the effectiveness of infliximab in Crohn's disease

References

• Torres J, Mehandru S, Colombel J-F, et al. Crohn's disease. Lancet. 2017;389(10080):1–10. doi: 10.1016/S0140-6736(16)31711-1.
   PubMed Web of Science ®Google Scholar
• Thia KT, Sandborn WJ, Harmsen WS, et al. Risk factors associated with progression to intestinal complications of Crohn's disease in a population-based cohort. Gastroenterology. 2010;139(4):1147–1155. doi: 10.1053/j.gastro.2010.06.070.
   PubMed Web of Science ®Google Scholar
• Peyrin-Biroulet L, Loftus EV, Colombel J-F, et al. The natural history of adult Crohn's disease in population-based cohorts. Am J Gastroenterol. 2010;105(2):289–297. doi: 10.1038/ajg.2009.579.
   PubMed Web of Science ®Google Scholar
• Donnellan CF, Yann LH, Lal S. Nutritional management of Crohn's disease. Therap Adv Gastroenterol. 2013;6(3):231–242. doi: 10.1177/1756283X13477715.
   PubMed Web of Science ®Google Scholar
• Balestrieri P, Ribolsi M, Guarino MPL, et al. Nutritional aspects in inflammatory bowel diseases. Nutrients. 2020;12:372. doi: 10.3390/nu12020372.
   PubMed Web of Science ®Google Scholar
• Nguyen GC, Munsell M, Harris ML. Nationwide prevalence and prognostic significance of clinically diagnosable protein-calorie malnutrition in hospitalized inflammatory bowel disease patients. Inflamm Bowel Dis. 2008;14(8):1105–1111. doi: 10.1002/ibd.20429.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ. Current directions in IBD therapy: what goals are feasible with biological modifiers? Gastroenterology. 2008;135(5):1442–1447. doi: 10.1053/j.gastro.2008.09.053.
   PubMed Web of Science ®Google Scholar
• Zhou Z, Zhang H-S, Liu Y, et al. Loss of TET1 facilitates DLD1 colon cancer cell migration via H3K27me3-mediated down-regulation of E-cadherin. J Cell Physiol. 2018;233(2):1359–1369. doi: 10.1002/jcp.26012.
   PubMed Web of Science ®Google Scholar
• Gomollón F, Dignass A, Annese V, et al. 3rd European evidence-based consensus on the diagnosis and management of Crohn's disease 2016: part 1: diagnosis and medical management. J Crohns Colitis. 2017;11(1):3–25. doi: 10.1093/ecco-jcc/jjw168.
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002;359(9317):1541–1549. doi: 10.1016/S0140-6736(02)08512-4.
   PubMed Web of Science ®Google Scholar
• Torres J, Bonovas S, Doherty G, et al. ECCO guidelines on therapeutics in Crohn's disease: medical treatment. J Crohns Colitis. 2020;14(1):4–22. doi: 10.1093/ecco-jcc/jjz180.
   PubMed Web of Science ®Google Scholar
• Schreiber S, Reinisch W, Colombel JF, et al. Subgroup analysis of the placebo-controlled CHARM trial: increased remission rates through 3 years for adalimumab-treated patients with early Crohn's disease. J Crohns Colitis. 2013;7(3):213–221. doi: 10.1016/j.crohns.2012.05.015.
   PubMed Web of Science ®Google Scholar
• Colombel JF, Reinisch W, Mantzaris GJ, et al. Randomised clinical trial: deep remission in biologic and immunomodulator naïve patients with Crohn's disease – a SONIC post hoc analysis. Aliment Pharmacol Ther. 2015;41(8):734–746. doi: 10.1111/apt.13139.
   PubMed Web of Science ®Google Scholar
• Maser EA, Villela R, Silverberg MS, et al. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. Clin Gastroenterol Hepatol. 2006;4(10):1248–1254. doi: 10.1016/j.cgh.2006.06.025.
   PubMed Web of Science ®Google Scholar
• Nanda KS, Cheifetz AS, Moss AC. Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis. Am J Gastroenterol. 2013;108(1):40–47; quiz 48. doi: 10.1038/ajg.2012.363.
   PubMed Web of Science ®Google Scholar
• Ben-Horin S, Chowers Y. Review article: loss of response to anti-TNF treatments in Crohn's disease. Aliment Pharmacol Ther. 2011;33(9):987–995. doi: 10.1111/j.1365-2036.2011.04612.x.
   PubMed Web of Science ®Google Scholar
• Billiet T, Papamichael K, de Bruyn M, et al. A matrix-based model predicts primary response to infliximab in Crohn's disease. J Crohns Colitis. 2015;9(12):1120–1126. doi: 10.1093/ecco-jcc/jjv156.
   PubMed Web of Science ®Google Scholar
• Li Y, Pan J, Zhou N, et al. A random Forest model predicts responses to infliximab in Crohn's disease based on clinical and serological parameters. Scand J Gastroenterol. 2021;56(9):1030–1039. doi: 10.1080/00365521.2021.1939411.
   PubMed Web of Science ®Google Scholar
• ten Hove T, van Montfrans C, Peppelenbosch MP, et al. Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease. Gut. 2002;50(2):206–211. doi: 10.1136/gut.50.2.206.
   PubMed Web of Science ®Google Scholar
• Onodera T, Goseki N, Kosaki G. [Prognostic nutritional index in gastrointestinal surgery of malnourished cancer patients. Nihon Geka Gakkai Zasshi. 1984;85:1001–1005.
   PubMedGoogle Scholar
• Fu M, Yu L, Yang L, et al. Predictive value of the preoperative prognostic nutritional index for postoperative progression in patients with pancreatic neuroendocrine neoplasms. Front Nutr. 2022;9:945833. doi: 10.3389/fnut.2022.945833.
   PubMed Web of Science ®Google Scholar
• Zencirkiran Agus H, Kahraman S. Prognostic nutritional index predicts one-year outcome in heart failure with preserved ejection fraction. Acta Cardiol. 2020;75(5):450–455. doi: 10.1080/00015385.2019.1661139.
   PubMed Web of Science ®Google Scholar
• Zhang J, Xiao X, Wu Y, et al. Prognostic nutritional index as a predictor of diabetic nephropathy progression. Nutrients. 2022;14:3634. doi: 10.3390/nu14173634.
   PubMed Web of Science ®Google Scholar
• Best WR, Becktel JM, Singleton JW, et al. Development of a Crohn's disease activity index. National cooperative Crohn's disease study. Gastroenterology. 1976;70(3):439–444. doi: 10.1016/S0016-5085(76)80163-1.
   PubMed Web of Science ®Google Scholar
• Vermeire S, Van Assche G, Rutgeerts P. C-reactive protein as a marker for inflammatory bowel disease. Inflamm Bowel Dis. 2004;10(5):661–665. doi: 10.1097/00054725-200409000-00026.
   PubMed Web of Science ®Google Scholar
• Mosli MH, Zou G, Garg SK, et al. C-Reactive protein, fecal calprotectin, and stool lactoferrin for detection of endoscopic activity in symptomatic inflammatory bowel disease patients: a systematic review and meta-analysis. Am J Gastroenterol. 2015;110(6):802–819; quiz 820. doi: 10.1038/ajg.2015.120.
   PubMed Web of Science ®Google Scholar
• Chang S, Malter L, Hudesman D. Disease monitoring in inflammatory bowel disease. World J Gastroenterol. 2015;21(40):11246–11259. doi: 10.3748/wjg.v21.i40.11246.
   PubMed Web of Science ®Google Scholar
• Lewis JD. The utility of biomarkers in the diagnosis and therapy of inflammatory bowel disease. Gastroenterology. 2011;140(6):1817.e2–1826.e2. doi: 10.1053/j.gastro.2010.11.058.
   Web of Science ®Google Scholar
• Zhou Y, Xu ZZ, He Y, et al. Gut microbiota offers universal biomarkers across ethnicity in inflammatory bowel disease diagnosis and infliximab response prediction. mSystems. 2018;3:e00188–e00217. doi: 10.1128/mSystems.00188-17.
   PubMed Web of Science ®Google Scholar
• Li L, Chen R, Zhang Y, et al. A novel model based on serum biomarkers to predict primary non-response to infliximab in Crohn's disease. Front Immunol. 2021;12:646673. doi: 10.3389/fimmu.2021.646673.
   PubMed Web of Science ®Google Scholar
• Magro F, Rodrigues-Pinto E, Santos-Antunes J, et al. High C-reactive protein in Crohn's disease patients predicts nonresponse to infliximab treatment. J Crohns Colitis. 2014;8(2):129–136. doi: 10.1016/j.crohns.2013.07.005.
   PubMed Web of Science ®Google Scholar
• Hibi T, Sakuraba A, Watanabe M, et al. C-reactive protein is an indicator of serum infliximab level in predicting loss of response in patients with Crohn's disease. J Gastroenterol. 2014;49(2):254–262. doi: 10.1007/s00535-013-0807-0.
   PubMed Web of Science ®Google Scholar
• Mirili C, Yılmaz A, Demirkan S, et al. Clinical significance of prognostic nutritional index (PNI) in malignant melanoma. Int J Clin Oncol. 2019;24(10):1301–1310. doi: 10.1007/s10147-019-01461-7.
   PubMed Web of Science ®Google Scholar
• Wang Z, Zhao L, He S. Prognostic nutritional index and the risk of mortality in patients with hypertrophic cardiomyopathy. Int J Cardiol. 2021;331:152–157. doi: 10.1016/j.ijcard.2021.01.023.
   PubMed Web of Science ®Google Scholar
• Stam F, van Guldener C, Schalkwijk CG, et al. Impaired renal function is associated with markers of endothelial dysfunction and increased inflammatory activity. Nephrol Dial Transplant. 2003;18(5):892–898. doi: 10.1093/ndt/gfg080.
   PubMed Web of Science ®Google Scholar
• Gecse KB, Brandse JF, van Wilpe S, et al. Impact of disease location on fecal calprotectin levels in Crohn's disease. Scand J Gastroenterol. 2015;50(7):841–847. doi: 10.3109/00365521.2015.1008035.
   PubMed Web of Science ®Google Scholar
• Fasanmade AA, Adedokun OJ, Olson A, et al. Serum albumin concentration: a predictive factor of infliximab pharmacokinetics and clinical response in patients with ulcerative colitis. Int J Clin Pharmacol Ther. 2010;48(5):297–308. doi: 10.5414/cpp48297.
   PubMed Web of Science ®Google Scholar
• Hemperly A, Vande Casteele N. Clinical pharmacokinetics and pharmacodynamics of infliximab in the treatment of inflammatory bowel disease. Clin Pharmacokinet. 2018;57(8):929–942. doi: 10.1007/s40262-017-0627-0.
   PubMed Web of Science ®Google Scholar
• Dotan I, Ron Y, Yanai H, et al. Patient factors that increase infliximab clearance and shorten half-life in inflammatory bowel disease: a population pharmacokinetic study. Inflamm Bowel Dis. 2014;20(12):2247–2259. doi: 10.1097/MIB.0000000000000212.
   PubMed Web of Science ®Google Scholar
• Brandse JF, Mould D, Smeekes O, et al. A real-life population pharmacokinetic study reveals factors associated with clearance and immunogenicity of infliximab in inflammatory bowel disease. Inflamm Bowel Dis. 2017;23(4):650–660. doi: 10.1097/MIB.0000000000001043.
   PubMed Web of Science ®Google Scholar
• Eksteen B, Liaskou E, Adams DH. Lymphocyte homing and its role in the pathogenesis of IBD. Inflamm Bowel Dis. 2008;14(9):1298–1312. doi: 10.1002/ibd.20453.
   PubMed Web of Science ®Google Scholar
• Dotan I, Allez M, Danese S, et al. The role of integrins in the pathogenesis of inflammatory bowel disease: approved and investigational anti-integrin therapies. Med Res Rev. 2020;40(1):245–262. doi: 10.1002/med.21601.
   PubMed Web of Science ®Google Scholar
• Selby WS, Jewell DP. T lymphocyte subsets in inflammatory bowel disease: peripheral blood. Gut. 1983;24(2):99–105. doi: 10.1136/gut.24.2.99.
   PubMed Web of Science ®Google Scholar
• Gordon AS. Some aspects of hormonal influences upon the leukocytes. Ann N Y Acad Sci. 1955;59(5):907–927. doi: 10.1111/j.1749-6632.1955.tb45990.x.
   PubMed Web of Science ®Google Scholar
• Toft P, Svendsen P, Tønnesen E, et al. Redistribution of lymphocytes after major surgical stress. Acta Anaesthesiol Scand. 1993;37(3):245–249. doi: 10.1111/j.1399-6576.1993.tb03708.x.
   PubMed Web of Science ®Google Scholar
• Tumpey TM, Lu X, Morken T, et al. Depletion of lymphocytes and diminished cytokine production in mice infected with a highly virulent influenza A (H5N1) virus isolated from humans. J Virol. 2000;74(13):6105–6116. doi: 10.1128/jvi.74.13.6105-6116.2000.
   PubMed Web of Science ®Google Scholar
• Mahid SS, Minor KS, Soto RE, et al. Smoking and inflammatory bowel disease: a meta-analysis. Mayo Clin Proc. 2006;81(11):1462–1471. doi: 10.4065/81.11.1462.
   PubMed Web of Science ®Google Scholar
• Higuchi LM, Khalili H, Chan AT, et al. A prospective study of cigarette smoking and the risk of inflammatory bowel disease in women. Am J Gastroenterol. 2012;107(9):1399–1406. doi: 10.1038/ajg.2012.196.
   PubMed Web of Science ®Google Scholar
• Avidan B, Sakhnini E, Lahat A, et al. Risk factors regarding the need for a second operation in patients with Crohn's disease. Digestion. 2005;72(4):248–253. doi: 10.1159/000089960.
   PubMed Web of Science ®Google Scholar
• Vermeire S, Louis E, Carbonez A, et al. Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's disease. Am J Gastroenterol. 2002;97(9):2357–2363. doi: 10.1111/j.1572-0241.2002.05991.x.
   PubMed Web of Science ®Google Scholar
• Lindholm CR, Siegel CA. Are We ready to include prognostic factors in inflammatory bowel disease trials? Curr Pharm Des. 2019;25(1):64–68. doi: 10.2174/1381612825666190312113935.
   PubMed Web of Science ®Google Scholar
• Alexdottir MS, Bourgonje AR, Karsdal MA, et al. Serological biomarkers of intestinal collagen turnover identify early response to infliximab therapy in patients with Crohn's disease. Front Med. 2022;9:933872. doi: 10.3389/fmed.2022.933872.
   Web of Science ®Google Scholar
• van Haaften WT, Mortensen JH, Dige AK, et al. Serological biomarkers of tissue turnover identify responders to anti-TNF therapy in Crohn's disease: a pilot study. Clin Transl Gastroenterol. 2020;11(9):e00217. doi: 10.14309/ctg.0000000000000217.
   PubMed Web of Science ®Google Scholar
• Andreou N-P, Legaki E, Dovrolis N, et al. B-cell activating factor (BAFF) expression is associated with Crohn's disease and can serve as a potential prognostic indicator of disease response to infliximab treatment. Dig Liver Dis. 2021;53(5):574–580. doi: 10.1016/j.dld.2020.11.030.
   PubMedGoogle Scholar
• Verstockt B, Verstockt S, Creyns B, et al. Mucosal IL13RA2 expression predicts nonresponse to anti-TNF therapy in Crohn's disease. Aliment Pharmacol Ther. 2019;49(5):572–581. doi: 10.1111/apt.15126.
   PubMed Web of Science ®Google Scholar
• Laharie D, Mesli S, El Hajbi F, et al. Prediction of Crohn's disease relapse with faecal calprotectin in infliximab responders: a prospective study. Aliment Pharmacol Ther. 2011;34(4):462–469. doi: 10.1111/j.1365-2036.2011.04743.x.
   PubMed Web of Science ®Google Scholar
• Ventin-Holmberg R, Eberl A, Saqib S, et al. Bacterial and fungal profiles as markers of infliximab drug response in inflammatory bowel disease. J Crohns Colitis. 2021;15(6):1019–1031. doi: 10.1093/ecco-jcc/jjaa252.
   PubMed Web of Science ®Google Scholar